Atnaujinkite slapukų nuostatas

El. knyga: Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop

  • Formatas: 142 pages
  • Išleidimo metai: 28-Oct-2020
  • Leidėjas: National Academies Press
  • Kalba: eng
  • ISBN-13: 9780309679626
Kitos knygos pagal šią temą:
  • Formatas: 142 pages
  • Išleidimo metai: 28-Oct-2020
  • Leidėjas: National Academies Press
  • Kalba: eng
  • ISBN-13: 9780309679626
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

On March 24, 2020, a 1-day public workshop titled The Role of Digital Health Technologies in Drug Development was convened by the National Academies of Sciences, Engineering, and Medicine. This workshop builds on prior efforts to explore how virtual clinical trials facilitated by digital health technologies (DHTs) might change the landscape of drug development. To explore the challenges and opportunities in using DHTs for improving the probability of success in drug R&D, enabling better patient care, and improving precision medicine, the workshop featured presentations and panel discussions on the integration of DHTs across all phases of drug development. Throughout the workshop, participants considered how DHTs could be applied to achieve the greatest impactand perhaps even change the face of how clinical trials are conductedin ways that are also ethical, equitable, safe, and effective. This publication summarizes the presentations and discussions from the workshop.

Table of Contents



Front Matter 1 Introduction 2 Ethical and Regulatory Considerations for Digital Health Technologies 3 Digital Health Technologies for Characterizing Disease 4 Digital Health Technologies for Recruitment and Safety 5 Digital Health Technologies for Pivotal Trials 6 Digital Health Technologies for Enhancing Real-World Evidence Collection, Patient Centricity, and Post-Market Studies 7 Reflections and Key Takeaways References Appendix A: Workshop Statement of Task Appendix B: Workshop Agenda Appendix C: Planning Committee Biographical Sketches Appendix D: Workshop Speaker Biographical Sketches
Acronyms And Abbreviations xxi
1 Introduction
1(4)
Use of Digital Health Technology Applications to Address Pain Points Across the Drug Development Lifecycle
2(1)
Organization of the Workshop
3(1)
Organization of the Proceedings
4(1)
2 Ethical And Regulatory Considerations For Digital Health Technologies
5(16)
Categories and Uses of Digital Health Technologies
6(4)
Using Digital Health Technologies to Capture Real-World Evidence
10(1)
Ethical, Legal, and Social Implications of Digital Health Technologies and Clinical Research
11(6)
Considerations for the Future
17(4)
3 Digital Health Technologies For Characterizing Disease
21(20)
Challenges in Deriving Health Insights from Real-World Sensor Data
23(4)
Digital Data Collection by the All of Us Research Program
27(4)
Adoption of Digital Health Technologies
31(3)
Discovery Through Person-Generated Health Data
34(4)
Discussion
38(3)
4 Digital Health Technologies For Recruitment And Safety
41(20)
Regulatory Perspective on Drug Development Tools
43(6)
Engaging the Public in Research Using Mobile Health
49(3)
Digital Health Technologies and Remote Monitoring in Drug Development
52(1)
Digital Health Technologies and the COVID-19 Pandemic
53(3)
Deploying Digital Health Technologies at the Intersection of Clinical Care and Research
56(4)
Discussion
60(1)
5 Digital Health Technologies For Pivotal Trials
61(14)
Industry Perspective on Digital Health Technologies in Pivotal Trials
62(3)
Performance Requirements for Digital Health Technologies in Pivotal Trials
65(4)
Regulatory Perspective on the Use of Digital Health Technologies in Pivotal Trials
69(3)
Discussion
72(3)
6 Digital Health Technologies For Enhancing Real-World Evidence Collection, Patient Centricity, And Post-Market Studies
75(12)
Digital Health Technologies for Post-Marketing Research and Surveillance
76(3)
Use of Digital Health Technologies to Empower Patient Participation
79(5)
Clinician Perspective on Digital Health Technologies for Post-Marketing Research and Surveillance
84(3)
7 Reflections And Key Takeaways
87(6)
Challenges Associated with the Use of Digital Health Technologies
87(1)
Digital Health Technologies to Enable Patient-Centered Drug Development
88(1)
Standards and Evaluation Frameworks
89(1)
"Pain Points" Across the Drug Development Process and Solutions Digital Health Technologies Can Provide
90(9)
References 93(6)
Appendixes
A Workshop Statement Of Task
99(2)
B Workshop Agenda
101(4)
C Planning Committee Biographical Sketches
105(8)
D Workshop Speaker Biographical Sketches
113